跳到正文
原文
Alnylam Pharmaceuticals· @Alnylam · X·· 10 小时前精选AI 评分67
AI 导读

Alnylam 宣布,其与再生元合作的一款 RNAi 疗法已获美国 FDA 批准,用于全身型重症肌无力(gMG)。这是 Alnylam 在不到九年内第 7 款由该公司发现并获批的 RNAi 疗法。

推荐理由

Alnylam 披露其第 7 款 RNAi 疗法获 FDA 批准,读者可据此了解 RNAi 平台在神经领域的落地节奏。

正文

The seventh Alnylam-discovered RNAi therapeutic in less than nine years has been approved by the U.S. FDA. Congratulations to our collaborator @Regeneron and to everyone who helped make this milestone possible. We are proud to see this therapy reach people living with generalized myasthenia gravis (gMG).

Read the full press release: https://go-alnylam.com/495YEg0

来源:Alnylam Pharmaceuticals · x.com